JP6117220B2 - 緩衝化された酸素療法剤 - Google Patents

緩衝化された酸素療法剤 Download PDF

Info

Publication number
JP6117220B2
JP6117220B2 JP2014535982A JP2014535982A JP6117220B2 JP 6117220 B2 JP6117220 B2 JP 6117220B2 JP 2014535982 A JP2014535982 A JP 2014535982A JP 2014535982 A JP2014535982 A JP 2014535982A JP 6117220 B2 JP6117220 B2 JP 6117220B2
Authority
JP
Japan
Prior art keywords
sucrose
ether
composition
ddfpe
perfluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014535982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528487A (ja
Inventor
エヴァン， シー． アンガー，
エヴァン， シー． アンガー，
ジェニファー， エル． ジョンソン，
ジェニファー， エル． ジョンソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvox Pharma LLC
Original Assignee
Nuvox Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvox Pharma LLC filed Critical Nuvox Pharma LLC
Publication of JP2014528487A publication Critical patent/JP2014528487A/ja
Application granted granted Critical
Publication of JP6117220B2 publication Critical patent/JP6117220B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014535982A 2011-10-13 2012-10-15 緩衝化された酸素療法剤 Active JP6117220B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/273,115 US8822549B2 (en) 2011-10-13 2011-10-13 Buffered oxygen therapeutic
US13/273,115 2011-10-13
PCT/US2012/060284 WO2013056246A1 (en) 2011-10-13 2012-10-15 Buffered oxygen therapeutic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017055752A Division JP6479870B2 (ja) 2011-10-13 2017-03-22 酸素療法剤の安定化方法

Publications (2)

Publication Number Publication Date
JP2014528487A JP2014528487A (ja) 2014-10-27
JP6117220B2 true JP6117220B2 (ja) 2017-04-19

Family

ID=48082584

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014535982A Active JP6117220B2 (ja) 2011-10-13 2012-10-15 緩衝化された酸素療法剤
JP2017055752A Active JP6479870B2 (ja) 2011-10-13 2017-03-22 酸素療法剤の安定化方法
JP2019020091A Active JP6789328B2 (ja) 2011-10-13 2019-02-06 酸素療法剤の安定化方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017055752A Active JP6479870B2 (ja) 2011-10-13 2017-03-22 酸素療法剤の安定化方法
JP2019020091A Active JP6789328B2 (ja) 2011-10-13 2019-02-06 酸素療法剤の安定化方法

Country Status (8)

Country Link
US (1) US8822549B2 (enExample)
EP (1) EP2766001B1 (enExample)
JP (3) JP6117220B2 (enExample)
CN (2) CN108685882A (enExample)
AU (1) AU2012323862B2 (enExample)
CA (2) CA2851522C (enExample)
IN (1) IN2014MN00880A (enExample)
WO (1) WO2013056246A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9700523B2 (en) * 2011-10-13 2017-07-11 Nuvox Pharma Llc Buffered oxygen therapeutic
US8822549B2 (en) * 2011-10-13 2014-09-02 Jennifer L. Johnson Buffered oxygen therapeutic
US20160206570A1 (en) * 2013-09-03 2016-07-21 Ariziba Board Of Regents On Behalf Of The University If Arizona Cardioprotectant to reduce damage from heart attack
EP3871666A1 (en) * 2014-03-05 2021-09-01 Evan C. Unger Fractionated radiotherapy and chemotherapy with an oxygen therapeutic
IL260206B2 (en) * 2015-12-21 2023-04-01 Nuvox Pharma Llc Preparations containing a nanoemulsion of fluorocarbons and methods for their preparation
CN115814325B (zh) * 2022-11-23 2024-04-19 浙江工业大学 一种含氟灭火剂组合物
EP4744487A1 (en) 2024-11-18 2026-05-20 NanoSanguis S.A. FLUID, FLUID PRODUCTION PROCESSES AND ITS USES
EP4744486A1 (en) 2024-11-18 2026-05-20 NanoSanguis S.A. PERFUSION FLUID, PRODUCTION PROCESSES FOR PERFUSION FLUID AND ITS USES.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423077A (en) * 1982-07-27 1983-12-27 The University Of Pennsylvania Perfluorochemical emulsion artificial blood
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5114932A (en) * 1990-11-30 1992-05-19 Runge Thomas M Hyperosmolar oxyreplete hemosubstitute
US5196199A (en) * 1990-12-14 1993-03-23 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and method of manufacture
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5595687A (en) 1992-10-30 1997-01-21 Thomas Jefferson University Emulsion stability
NZ262237A (en) 1993-01-25 1997-06-24 Sonus Pharma Inc Ultrasound contrast agents comprising phase shift colloids having a boiling point below the body temperature of the animal it is used in
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US20030032879A1 (en) 1997-07-07 2003-02-13 Steven Quay Microbubble formation using ultrasound
US7357937B2 (en) * 2002-09-24 2008-04-15 Therox, Inc. Perfluorocarbon emulsions with non-fluorinated surfactants
WO2010121082A2 (en) 2009-04-15 2010-10-21 Oxygen Biotherapeutics, Inc. Emulsions of perfluorocarbons
US8822549B2 (en) * 2011-10-13 2014-09-02 Jennifer L. Johnson Buffered oxygen therapeutic

Also Published As

Publication number Publication date
CA3057480C (en) 2021-07-20
JP2017132789A (ja) 2017-08-03
AU2012323862B2 (en) 2015-07-09
EP2766001B1 (en) 2024-05-15
EP2766001C0 (en) 2024-05-15
EP2766001A1 (en) 2014-08-20
IN2014MN00880A (enExample) 2015-04-17
US8822549B2 (en) 2014-09-02
WO2013056246A1 (en) 2013-04-18
JP2019089816A (ja) 2019-06-13
CA3057480A1 (en) 2013-04-18
JP6479870B2 (ja) 2019-03-06
CN104039317A (zh) 2014-09-10
CA2851522A1 (en) 2013-04-18
CN108685882A (zh) 2018-10-23
JP2014528487A (ja) 2014-10-27
AU2012323862A1 (en) 2014-05-29
JP6789328B2 (ja) 2020-11-25
US20130096204A1 (en) 2013-04-18
EP2766001A4 (en) 2015-06-10
CA2851522C (en) 2019-11-26
CN104039317B (zh) 2018-05-25

Similar Documents

Publication Publication Date Title
JP6479870B2 (ja) 酸素療法剤の安定化方法
CN1066963C (zh) 造影剂及其改进
CN1092988C (zh) 热稳定的造影剂
JP2835985B2 (ja) 皮膚外用クリーム製剤
SK93095A3 (en) Biocompatible contrast agent and dispersion with its contents
CN1158082A (zh) 装有用于诊断和治疗的多相组合物的容器
JPH11507873A (ja) 最適サイズのガス−充填小胞を作成するための装置および方法
JPH10500691A (ja) コンピューター連動断層撮影用造影剤として、安定化された均質な懸濁液
CN1213972A (zh) 造影剂或有关造影剂的改进
CN1182875C (zh) 给药前经连续输注使含气体的造影剂与冲洗介质混合的方法
AU2022201065A1 (en) Lipid-encapsulated gas microsphere compositions and related methods
Chattaraj et al. Ultrasound responsive Noble gas microbubbles for applications in image‐guided gas delivery
PT2197492E (pt) Novas composições à base de taxóides
SK108696A3 (en) Gas-containing microparticles, agents containing them, their use in medical diagnosis by ultrasonic techniques and methods of producing said particles and agents
PT86644B (pt) Processo para a preparacao de formulacoes secas contendo um sal de diclofenac
US9700523B2 (en) Buffered oxygen therapeutic
WO2007015510A1 (ja) 熱的に不安定な薬物の分解抑制方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170322

R150 Certificate of patent or registration of utility model

Ref document number: 6117220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250